Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: Aaron S. Mansfield, Stephen V. Liu, Aleksandra Szczęsna, Libor Havel, Maciej Kzrakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony S. Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Fairooz Kabbinavar, Alan Sandler, Leora Horn
Institutions: Mayo Clinic, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Thomayer University Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Ludwig Boltzmann Institute for Lung Health, Otto Wagner Hospital, Semmelweis University, Sarah Cannon, Tennessee Oncology, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, German Center for Lung Research, LungenClinic Grosshansdorf, Chinese University of Hong Kong, Genentech, Roche (China), Vanderbilt University, Vanderbilt University Medical Center
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235741007